🔬 Latest pharma industry updates 👇

🤝 Biogen will acquire RayThera for up to $1B, adding preclinical and early immunology small molecules.

💉 Moderna’s mRNA flu vaccine won unanimous FDA advisory panel support for adults aged 50 and older.

🙏 MilliporeSigma and KBI Biopharma formed an alliance to offer integrated ADC development and manufacturing services, combining mAb production with bioconjugation expertise.

🩸 Johnson & Johnson‘s Talvey gained momentum in earlier multiple myeloma after new combination data with Darzalex Faspro supported broader use of the bispecific immunotherapy.

💰 Kardigan raised $400M in its IPO, extending 2026’s strong biotech listing streak and making it the 4th biotech this year to raise at least $400M publicly.

🚨 The Bundibugyo Ebola outbreak in DRC surpassed 800 confirmed cases and 192 deaths, with contact tracing far below target and MSF warning the real scale remains unknown.

🧬 Eli Lilly and Company’s pirtobrutinib combination cut progression or death risk by 45% in relapsed or refractory CLL/SLL, supporting planned global filings for a broader indication.

📈 Outlook Therapeutics, Inc.’s Lytenava BLA resubmission for wet AMD was accepted for Class 1 FDA review, with a July 29, 2026 PDUFA date, sending shares higher.

🧠 uniQure plans to file AMT-130 for accelerated FDA approval in Huntington’s disease after regulators accepted three-year Phase 1/2 data as the primary basis for review.

🤝 Jazz Pharmaceuticals partnered with AbCellera to discover next-generation T-cell engagers for solid tumors for up to $792M per program.

🎯 Johnson & Johnson CEO ruled out entering GLP-1 obesity drugs, saying the company will focus instead on becoming oncology leader by 2030 and expanding in neuroscience.

🤝 Eli Lilly and Company will acquire 4E Therapeutics Inc., adding non-opioid pain programs led by MNK inhibitor 4ET1103 for nerve-damage pain, continuing its push into safer pain therapies.

🟢 GSK won FDA approval for Utebzi, the world’s 1st oral carbapenem, enabling stable patients with complicated urinary tract infections to leave hospital earlier and complete treatment at home.

📉 Legend Biotech priced a $226M ADS offering to strengthen its balance sheet, though dilution concerns pushed shares lower.

💰 cAMPfield Therapeutics launched with $180M Series A to develop prifemilast, an oral PDE4 inhibitor for inflammatory bowel disease.

🤖 Midjourney unveiled an ultrasound-based whole-body scanner developed with Butterfly Network, Inc., promising radiation-free 60-second 3D imaging.

----------

🤝 I’ll be attending BOS in Basel starting June 30th, happy to meet there!